News · 26 weeks440%
2026-03-012026-08-23
Mix2890d
- SEC Filings15(54%)
- Other5(18%)
- Earnings3(11%)
- Insider3(11%)
- Offering2(7%)
Latest news
25 items- SECSEC Form PRE 14A filed by Aethlon Medical Inc.PRE 14A - AETHLON MEDICAL INC (0000882291) (Filer)
- PRPresenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Presenting Today – Wednesday August 19, 2026 8:30Virtual Lobby opens.Register for the Con
- PRPresenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Day 1 - WednesdayAugust 19, 2026 8:30Virtual Lobby opens.Register for the Conference. I
- SECSEC Form 10-Q filed by Aethlon Medical Inc.10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® ProgramConference Call Today at 4:30 p.m. ETSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update. "We advanced our clinical and research programs during the quarter," said James Frakes, CEO and CFO. "We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier. We also had a Long COVID manuscript accepted for publication, which strengthens
- PRAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2026, at 4:15 p.m. ET on Thursday, August 13, 2026. Management will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10211144/104a3acc428.
- SECAethlon Medical Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRPresenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live streamMIAMI, July 15, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday July 15, 2026 11:00Virtual Lobby opens.Register for the Conference. If you already registered
- PRAethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohortsSAN DIEGO, July 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first cohort following treatment with the investigational Hemopurifier®. Replicating these findings in a second group of patients strengthens the scientific rationale for the Co
- SECAethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form 424B3 filed by Aethlon Medical Inc.424B3 - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form EFFECT filed by Aethlon Medical Inc.EFFECT - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesSAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 5,633,009 shares of its common stock at a combined public offering price of $0.7101 per share (or pre-funded warrant) and accompanying warrant, priced at-the-market under applicable Nasdaq rules. The warrants will have an exercise price of $0.7101 per share, will be exercisable upon the date of stockholder approval, and
- INSIDERDirector Shah Chetan covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 9% to 20,840 units (SEC Form 4) (withholding obligation)4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERDirector Gikakis Nicolas covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 10% to 20,663 units (SEC Form 4) (tax liability)4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERDirector Broenniman Edward G covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 5% to 22,363 units (SEC Form 4) (for withholding tax)4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- SECAmendment: SEC Form S-1/A filed by Aethlon Medical Inc.S-1/A - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAmendment: SEC Form S-1/A filed by Aethlon Medical Inc.S-1/A - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatmentSAN DIEGO, June 26, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin in
- SECSEC Form S-1 filed by Aethlon Medical Inc.S-1 - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form S-8 filed by Aethlon Medical Inc.S-8 - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form 10-K filed by Aethlon Medical Inc.10-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate UpdateAustralian oncology study advances into Cohort 3 as enrollment continuesEntered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses.Conference Call Today at 4:30 p.m. ETSAN DIEGO, June 10, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments. Key Highlight
AEMD FAQ
6 questionsWhat does Aethlon Medical Inc. do?
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for...Where does AEMD stock trade?
Aethlon Medical Inc. (AEMD) is listed on NASDAQ.What sector and industry is AEMD in?
Aethlon Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about AEMD?
Aethlon Medical Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $150.00 price target on 2025-07-07.What companies are similar to AEMD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare AEMD side-by-side with any of them on Quantisnow.How can I track AEMD on Quantisnow?
Quantisnow aggregates Aethlon Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AEMD to receive live email and push alerts on every new disclosure.